跳到正文
原文
Medical Xpress·· 23 天前精选AI 评分82

trastuzumab rezetecan 在 ERBB2 低表达晚期乳腺癌 III 期试验中延长无进展生存期但毒性更高

Targeted drug significantly delays advanced breast cancer progression but increases toxicity, phase III trial reports

AI 导读

HORIZON-Breast06 III 期随机试验显示,抗体偶联药物 trastuzumab rezetecan 治疗 ERBB2 低表达晚期或转移性乳腺癌的中位无进展生存期为 16.4 个月,标准化疗为 6.8 个月,疾病进展或死亡风险比为 0.27。

推荐理由

III 期随机对照数据显示该 ADC 将中位无进展生存期从 6.8 个月延长至 16.4 个月,同时重度不良反应发生率更高。

正文
Targeted drug trastuzumab rezetecan delays advanced breast cancer but increases toxicity, reports phase 3 trial
Trastuzumab rezetecan outperformed standard chemotherapy across all key measures of treatment effectiveness for patients with ERBB2-low breast cancer. Credit: Pexels

In a global phase 1 trial, trastuzumab rezetecan showed promising signs of fighting ERBB2-low metastatic breast cancer in patients who had already undergone extensive treatment. Also known as HER2-low breast cancer, this subtype is characterized by low levels of HER2, a growth factor protein that can still be targeted for treatment. Trastuzumab rezetecan is an antibody-drug conjugate (ADC) that works like a guided missile, seeking out tumor cells expressing low levels of ERBB2 and delivering a toxic chemotherapy payload directly inside them.

A recent phase 3 clinical trial called the HORIZON-Breast06 trial set out to evaluate whether a targeted cancer drug such as trastuzumab rezetecan works better than standard chemotherapy for patients with advanced or metastatic ERBB2-low breast cancer. After analyzing results from 551 female patients across 73 hospitals in China, researchers found that patients receiving trastuzumab rezetecan had over a year of breathing room before their cancer started growing again.

The median time without tumor growth or disease progression in the drug group was 16.4 months, compared with 6.8 months on standard chemotherapy. Patients on trastuzumab rezetecan faced just 27% (hazard ratio of 0.27) of the risk of disease progression or death that patients on standard chemotherapy did.

The findings and an editorial are published in JAMA.

Targeted drug trastuzumab rezetecan delays advanced breast cancer but increases toxicity, reports phase 3 trial
Kaplan-Meier Analysis of Progression-Free Survival (PFS) by Hormone Receptor Status. Credit: JAMA (2026). DOI: 10.1001/jama.2026.21372

Targeted latching onto cancer cells

Breast cancer is the most common cancer in 164 of 186 countries, claiming an estimated 694,000 lives worldwide in 2024 alone. Around 80% of breast cancers occur in women without any specific risk factors beyond their sex and age. Although far less common, breast cancer also affects men, who account for 0.5%–1% of all cases.

Not all breast cancers are alike. They are divided into different molecular subtypes based on factors such as the levels of a protein called ERBB2, formerly known as HER2/neu, which is an important target for treatment. Patients with ERBB2-low breast cancer have low levels of this protein or test negative on certain follow-up tests. Medical practice has found that they benefit very little from traditional ERBB2-targeted therapies and face a poorer prognosis than patients whose tumors have high ERBB2 levels.

Antibody-drug conjugates (ADCs), such as trastuzumab rezetecan, offer a way to tackle a longstanding challenge in treating ERBB2-low breast cancer. These drugs latch onto cancer cells carrying the ERBB2 protein, enter the cells and release a chemotherapy drug that kills them from within. Despite their promising initial outcomes, researchers knew little about how well these treatments worked in patients with hormone receptor-negative (HR-negative), ERBB2-low breast cancer who had not received chemotherapy for metastatic disease.

For HORIZON-Breast06, the researchers designed a randomized phase 3 clinical trial that enrolled 551 female patients with centrally confirmed ERBB2-low (HER2-low) advanced or metastatic breast cancer. The study was conducted across 73 centers in China, where the patients were randomly split into two groups of similar size. One group received trastuzumab rezetecan at 6.4 mg/kg intravenously every three weeks, and the other received a physician's choice of standard chemotherapy.

Benefits but with caveats

Trastuzumab rezetecan outperformed standard chemotherapy across all key measures of treatment effectiveness in patients with advanced ERBB2-low breast cancer. Tumors shrank in 75.5% of patients receiving the drug, compared with 41.2% of those on chemotherapy. Patients also went longer without their cancer worsening, with median progression-free survival exceeding 16 months in both hormone receptor-positive and hormone receptor-negative groups.

These gains, however, came with a trade-off. Severe treatment-related side effects such as blood toxicity or lung inflammation occurred in 84.1% of patients receiving trastuzumab rezetecan, compared with 67.9% of those on chemotherapy. More than half of the patients treated with trastuzumab rezetecan also needed at least one dose reduction to manage these side effects.

The researchers noted that while the drug significantly improved progression-free survival, health care providers will have to be more proactive in monitoring fluctuations in patients' health markers to better manage side effects.

Written for you by our author Sanjukta Mondal, edited by Gaby Clark, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

Maria Fernanda Mosele et al., Trastuzumab Rezetecan in ERBB2-Low Metastatic Breast Cancer, JAMA (2026). DOI: 10.1001/jama.2026.22295

Ying Fan et al., Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer, JAMA (2026). DOI: 10.1001/jama.2026.21372

Journal information: Journal of the American Medical Association

Clinical categories

Oncology

Who's behind this story?

Sanjukta Mondal

Sanjukta Mondal

Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: Targeted drug significantly delays advanced breast cancer progression but increases toxicity, phase III trial reports (2026, October 27) retrieved 27 October 2026 from https://medicalxpress.com/news/2026-10-drug-significantly-delays-advanced-breast.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com